Antares Pharma, Inc. (NASDAQ:ATRS) released its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.03), Briefing.com reports. Antares Pharma had a negative net margin of 34.27% and a negative return on equity of 41.37%. The business had revenue of $15.10 million for the quarter, compared to analysts’ expectations of $14.01 million. The firm’s quarterly revenue was up 11.9% compared to the same quarter last year.

Antares Pharma (NASDAQ ATRS) opened at $1.79 on Wednesday. Antares Pharma has a 1 year low of $1.50 and a 1 year high of $4.09. The company has a quick ratio of 3.04, a current ratio of 3.47 and a debt-to-equity ratio of 0.61.

A number of analysts have recently weighed in on the stock. Piper Jaffray Companies set a $3.00 price target on shares of Antares Pharma and gave the company a “buy” rating in a report on Monday, October 23rd. HC Wainwright lowered their price target on shares of Antares Pharma from $5.00 to $3.50 and set a “buy” rating on the stock in a report on Monday, October 23rd. ValuEngine cut shares of Antares Pharma from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. Finally, Vetr upgraded shares of Antares Pharma from a “buy” rating to a “strong-buy” rating and set a $3.42 target price for the company in a research note on Monday, July 24th. One research analyst has rated the stock with a sell rating, three have issued a buy rating and two have issued a strong buy rating to the company’s stock. Antares Pharma has an average rating of “Buy” and a consensus price target of $3.84.

COPYRIGHT VIOLATION WARNING: “Antares Pharma, Inc. (ATRS) Releases Earnings Results, Hits Expectations” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/11/08/antares-pharma-inc-atrs-releases-earnings-results-hits-expectations.html.

In other Antares Pharma news, Director Thomas J. Garrity sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 3rd. The shares were sold at an average price of $3.50, for a total transaction of $105,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Leonard S. Jacob sold 230,000 shares of the firm’s stock in a transaction that occurred on Monday, October 9th. The stock was sold at an average price of $4.05, for a total transaction of $931,500.00. The disclosure for this sale can be found here. Company insiders own 11.60% of the company’s stock.

Antares Pharma Company Profile

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.

Earnings History for Antares Pharma (NASDAQ:ATRS)

Receive News & Stock Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related stocks with our FREE daily email newsletter.